4//SEC Filing
Rovaldi Christopher 4
Accession 0001209191-22-023037
CIK 0001664710other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 4:31 PM ET
Size
16.4 KB
Accession
0001209191-22-023037
Insider Transaction Report
Form 4
Rovaldi Christopher
Chief Operating Officer
Transactions
- Sale
Common Stock
2022-04-01$54.34/sh−2$109→ 862 total - Sale
Common Stock
2022-04-01$56.20/sh−104$5,845→ 758 total - Sale
Common Stock
2022-04-01$56.89/sh−287$16,327→ 471 total - Exercise/Conversion
Common Stock
2022-04-01$16.00/sh+864$13,824→ 864 total - Sale
Common Stock
2022-04-01$57.97/sh−366$21,217→ 105 total - Sale
Common Stock
2022-04-01$58.83/sh−105$6,177→ 0 total - Exercise/Conversion
Employee Stock Option (right to buy)
2022-04-01−864→ 9,730 totalExercise: $16.00Exp: 2030-04-07→ Common Stock (864 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.50 to $56.23 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.50 to $57.43 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.58 to $58.26 inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.62 to $59.275 inclusive.
- [F6]One-fourth (1/4th) of the shares subject to the option vested on January 1, 2021, and one-twelfth (1/12th) of the remaining shares subject to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such date.
Documents
Issuer
Keros Therapeutics, Inc.
CIK 0001664710
Entity typeother
Related Parties
1- filerCIK 0001706040
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 4:31 PM ET
- Size
- 16.4 KB